刚刚，AI科学应用领域又有一件大事发生！ 谷歌与耶鲁大学的科学家们联合发布了一个大模型Cell2Sentence-Scale 27B（C2S-Scale）。 该模型提出了一个关于癌细胞行为的全新假设，并在多次体外实验中得到验证。 这一发现引发广泛关注，它展示了人工智能模型生成原创科学假设的潜力，有望由此打开一条人类抗癌的新途径。 网友prinz在x平台上评价道，「这表明该模型并非简单重复已知事实，而是生成了新的、可验证的科学假设。」 C2S-Scale基于Google的开源Gemma模型构建，训练语料涵盖超过10亿个Token的转录组数据、生物学文献与元数据，从而使其具备跨维度解析细胞行为的 能力。 目前，耶鲁大学的研究团队正在推进AI在其他免疫学情境中生成更多科学预测，这一机制的出现有望加速抗癌新疗法的研发步伐。 研究人员还在bioRxiv上公开了论文的预印本，目前该论文正在经历「同行评审」阶段。 论文地址https://www.biorxiv.org/content/10.1101/2025.04.14.648850v2.full.pdf+html AI不是只懂复现 而其余候选则是从未被报道过的新发现，这 ...

Summary of the Conference Call for Ascentage Pharma Company Overview - **Company**: Ascentage Pharma - **Focus**: Development of innovative anti-cancer therapies, particularly BCL-2 selective inhibitors and MDM2-P53 pathway inhibitors Key Points Industry and Product Highlights - **APG2,575**: A selective BCL-2 inhibitor showing significant efficacy in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) - Overall Response Rate (ORR) in treatment-naive patients is 83% and 43% in relapsed/refractory patients - ORR of 31% in patients previously treated with Venetoclax, indicating potential for hard-to-treat cases [2][4] - Faster onset of action (Tmax of 3-8 hours vs. 25-30 hours for Venetoclax) and shorter half-life (3-5 hours vs. 25-30 hours) [2][6] - Lower incidence of tumor lysis syndrome compared to Venetoclax [6] - **APG115**: An MDM2-P53 pathway inhibitor with potential applications across various cancer types - Clinical data presented at ASCO showed promising results, particularly in neuroendocrine tumors (ACC) [2][7][11] - In a Phase II trial, 2 complete responses and significant disease stabilization were observed [11] Clinical Development Plans - Ascentage Pharma plans to continue advancing APG2,575 and APG115 through global clinical trials, including registration studies for high-risk MDS and treatment-naive AML patients [4][12] - Ongoing discussions with regulatory bodies regarding the next steps for APG115 registration studies [12] Competitive Landscape - Venetoclax has shown lower infection rates and better tolerability in nearly 100 AML and MDS patients, establishing it as a standard treatment [10] - Ascentage Pharma is positioned as the second company globally to enter BCL-2 inhibitor clinical trials, with IND approval obtained [16] Future Directions - The company aims to strengthen collaborations with leading research institutions and companies to accelerate the development of new anti-cancer therapies [9][25] - Focus on expanding clinical trials and exploring combination therapies to address unmet medical needs in oncology [25] Market Potential - The market for multiple myeloma is substantial, with sales exceeding $30 billion in 2024, and Ascentage's BCL-2 inhibitors are expected to play a significant role [23][24] - The company is exploring registration clinical plans for multiple myeloma based on promising safety and efficacy data [24] Additional Insights - The company is actively pursuing global registration studies and expanding patient enrollment in ongoing trials [15][21] - Emphasis on the importance of safety and tolerability in the development of BCL-2 inhibitors, especially in comparison to existing therapies [18][24] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Ascentage Pharma's commitment to advancing innovative cancer therapies and addressing significant market opportunities.